結締組織疾病治療市場規模、佔有率和成長分析：按藥物類別、疾病類型、通路、最終用戶和地區分類－2026-2033年產業預測

2024 年全球結締組織疾病治療市場價值為 85.2 億美元，預計到 2025 年將成長至 90.6 億美元，到 2033 年將成長至 148.5 億美元，在預測期（2026-2033 年）內複合年成長率為 6.32%。

在全球結締組織疾病治療市場快速發展的推動下，藥物、生物製藥和創新基因療法的進步日益顯著。這些疾病盛行率的不斷上升以及由此帶來的長期醫療保健成本負擔凸顯了該市場的重要性。生物製藥的核准在市場成長中發揮了關鍵作用，尤其是Janus激酶（JAK）抑制劑的出現，這類藥物能夠迅速緩解症狀。基因組分析能夠為患者配對最佳標靶治療，從而提高治療的準確性和成本效益，並減少不必要的處方。採用精準醫療策略的醫院能夠更快地獲得保險報銷，這反過來又鼓勵了他們對伴隨診斷的投資。住院率的顯著下降清楚地表明了引入基於生物標記的療法所帶來的經濟效益。

全球結締組織疾病治療市場的成長要素

全身性紅斑性狼瘡和硬皮症自體免疫疾病的日益流行，導致需要接受專門結締組織疾病治療的患者數量顯著增加。為因應這一激增，醫療機構和製藥公司正投入資源研發和推廣標靶治療，透過提高需求和加強跨醫療機構的臨床整合，推動市場成長。此外，這些進展也促進了學術界和產業界相關人員之間的合作，加速了新產品的上市，並推動了創新，從而拓展了患者的治療選擇。最終，這一趨勢將推動該細分市場持續擴張。

全球結締組織疾病治療市場阻礙因素

生物製藥治療的高昂成本給醫療系統、保險公司和患者帶來了巨大的經濟挑戰。這往往導致保險覆蓋範圍有限，患者難以獲得創新治療方案。因此，藥物選擇委員會傾向於優先考慮成本效益高的替代方案，而醫療專業人員也往往不願意開立昂貴的藥物。這些價格壓力阻礙了生物製劑的廣泛應用，並限制了製造商在各種經濟狀況下擴大分銷管道的潛在利潤，從而減緩了市場成長。此外，這些經濟限制也促使人們對生物相似藥產生興趣，進而影響治療領域的支出重點。

全球結締組織疾病治療市場趨勢

全球結締組織疾病治療市場正呈現出顯著的創新生物標記發現趨勢，這些生物標記正在革新此類複雜疾病的診斷和治療方法。疾病特異性生物標記的出現有助於早期檢測和早期療育，使臨床醫生能夠利用分子特徵進行有效的患者分層和個人化治療。這一趨勢推動了針對患者個別需求的標靶治療，最大限度地減少了對廣譜免疫抑制劑的依賴，並最終帶來更好的臨床療效。隨著生技公司加強合作，共同開發伴隨診斷，市場正處於向實證醫學模式轉變的邊緣，這種模式已被醫療保健系統和保險公司廣泛接受，標誌著精準醫療正逐步引入結締組織疾病治療領域。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球結締組織疾病治療市場規模：依藥物類別分類

• 皮質類固醇
• 免疫抑制劑
• 生物製藥（Rituximab、貝利木單抗）
• NSAIDs

全球結締組織疾病治療市場規模：依疾病類型分類

• 狼瘡
• 硬皮症
• 修格蘭氏症候群
• 混合性結締組織疾病

全球結締組織疾病治療市場規模：依通路分類

• 醫院藥房
• 專科藥房

全球結締組織疾病治療市場規模：依最終用戶分類

• 風濕病診所
• 醫院

全球結締組織疾病治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• GlaxoSmithKline（Benlysta）
• Roche（Rituxan）
• AstraZeneca（Saphnelo）
• Eli Lilly
• Bristol Myers Squibb
• Pfizer Inc.
• AbbVie Inc.
• Aurinia Pharmaceuticals
• Biogen Inc.
• UCB SA
• Argenx SE
• Horizon Therapeutics（Amgen）
• Idorsia Pharmaceuticals
• Aurinia Pharmaceuticals
• ImmunoGen Inc.
• Akros Pharma
• Equillium Inc.
• Provention Bio（Sanofi）
• Kezar Life Sciences
• Resolve Therapeutics

結論與建議

Global Connective Tissue Disease Treatment Market size was valued at USD 8.52 Billion in 2024 and is poised to grow from USD 9.06 Billion in 2025 to USD 14.85 Billion by 2033, growing at a CAGR of 6.32% during the forecast period (2026-2033).

The global market for connective tissue disease treatments is rapidly evolving, driven by advancements in pharmaceuticals, biologics, and innovative gene therapies targeting prevalent autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, and scleroderma. The increasing prevalence of these conditions, alongside the associated long-term healthcare costs, underscores the significance of this market. Biologic approvals have been pivotal to growth, particularly with the advent of Janus-kinase inhibitors that offer rapid symptom relief. Genomic profiling enhances treatment precision by aligning patients with targeted therapies, improving cost-effectiveness and reducing unnecessary prescribing efforts. Hospitals adopting precision medicine strategies benefit from quicker reimbursements, encouraging investments in companion diagnostics. Noteworthy reductions in hospital admissions showcase the economic benefits linked to biomarker-guided therapy adoption.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Connective Tissue Disease Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Connective Tissue Disease Treatment Market Segments Analysis

Global connective tissue disease treatment market is segmented by drug class, disease type, distribution, end-user and region. Based on drug class, the market is segmented into Corticosteroids, Immunosuppressants, Biologics (Rituximab, Belimumab) and NSAIDs. Based on disease type, the market is segmented into Lupus, Scleroderma, Sjogren's Syndrome and Mixed Connective Tissue Disease. Based on distribution, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on end-user, the market is segmented into Rheumatology Clinics and Hospitals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Connective Tissue Disease Treatment Market

The rising prevalence of autoimmune disorders like systemic lupus erythematosus and scleroderma is significantly increasing the patient population in need of specialized connective tissue disease therapies. This surge prompts healthcare providers and pharmaceutical companies to allocate resources towards developing and implementing targeted treatments, which in turn fuels market growth through elevated demand and enhanced clinical integration in various healthcare environments. Furthermore, these advancements stimulate partnerships between academic institutions and industry stakeholders, nurturing innovation that accelerates the introduction of new products and broadens therapeutic choices for patients. This dynamic ultimately bolsters momentum for continued expansion within the market segment.

Restraints in the Global Connective Tissue Disease Treatment Market

The high costs linked to biologic therapies create substantial financial challenges for healthcare systems, insurance providers, and patients. This often leads to limited reimbursement approvals and restricted access to innovative treatment options. As a result, formulary committees tend to favor more cost-effective alternatives, which can discourage healthcare professionals from prescribing pricier products. Such pricing pressures slow down market growth by hindering wider adoption and limiting revenue potential for manufacturers aiming to expand distribution in various economic conditions. Additionally, these financial constraints stimulate interest in biosimilar alternatives, thereby influencing spending priorities within the treatment landscape.

Market Trends of the Global Connective Tissue Disease Treatment Market

The Global Connective Tissue Disease Treatment market is witnessing a significant trend towards innovative biomarker discovery, which is revolutionizing diagnostic and therapeutic approaches for these complex conditions. The emergence of disease-specific biomarkers is enhancing early detection and intervention, allowing clinicians to utilize molecular signatures for effective patient stratification and treatment personalization. This trend minimizes the dependency on broad-spectrum immunosuppressants by facilitating targeted therapy that is tailored to individual patient needs, ultimately leading to better clinical outcomes. As biotech companies intensify collaborations to develop companion diagnostics, the market is poised for a shift towards evidence-based care models that are widely embraced across healthcare systems and payer networks, indicating a progressive adoption of precision medicine in the treatment landscape for connective tissue diseases.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Connective Tissue Disease Treatment Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Corticosteroids
• Immunosuppressants
• Biologics (Rituximab, Belimumab)
• NSAIDs

Global Connective Tissue Disease Treatment Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Lupus
• Scleroderma
• Sjogren's Syndrome
• Mixed Connective Tissue Disease

Global Connective Tissue Disease Treatment Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies

Global Connective Tissue Disease Treatment Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Rheumatology Clinics
• Hospitals

Global Connective Tissue Disease Treatment Market Size & CAGR (2026-2033)

• North America (Drug Class, Disease Type, Distribution, End-User)
  • US
  • Canada
• Europe (Drug Class, Disease Type, Distribution, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Disease Type, Distribution, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Disease Type, Distribution, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Disease Type, Distribution, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• GlaxoSmithKline (Benlysta)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Rituxan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (Saphnelo)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurinia Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Argenx SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Therapeutics (Amgen)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Idorsia Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurinia Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ImmunoGen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akros Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Equillium Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Provention Bio (Sanofi)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kezar Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Resolve Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations